Last $1.35 USD
Change Today -0.06 / -4.26%
Volume 3.4M
CLRX On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

collabrx inc (CLRX) Snapshot

Open
$1.39
Previous Close
$1.41
Day High
$1.55
Day Low
$1.31
52 Week High
03/10/14 - $3.60
52 Week Low
12/23/14 - $0.51
Market Cap
13.1M
Average Volume 10 Days
5.2M
EPS TTM
$-1.83
Shares Outstanding
9.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for COLLABRX INC (CLRX)

Related News

No related news articles were found.

collabrx inc (CLRX) Related Businessweek News

No Related Businessweek News Found

collabrx inc (CLRX) Details

CollabRx, Inc. provides cloud-based expert systems to inform healthcare decision-making. The company’s cloud-based expert systems provide clinical knowledge to institutions, physicians, researchers, and patients for genomics-based medicine in cancer. It offers CollabRx Therapy Finder, a series of cancer-specific Web-based system applications that are accessed by physicians and patients. The company was formerly known as Tegal Corporation and changed its name to CollabRx, Inc. in September 2012. CollabRx, Inc. was founded in 1972 and is headquartered in San Francisco, California.

15 Employees
Last Reported Date: 02/17/15
Founded in 1972

collabrx inc (CLRX) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $285.1K
Chair of The Editorial Advisory Board, Editor...
Total Annual Compensation: $139.4K
Chief Operating Officer and Vice President
Total Annual Compensation: $13.8K
Vice President of Business Development and St...
Total Annual Compensation: $182.4K
Consultant and Director
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

collabrx inc (CLRX) Key Developments

CollabRx Regains Compliance on Bid Price

CollabRx, Inc. announced that it had received notice from the NASDAQ OMX GROUP (Nasdaq) that the Company had regained compliance with the $1.00 minimum bid price as required by Listing Rule 5550(a)(2). Since being notified on November 18, 2014 that the Company had until May 18, 2015 to regain compliance, the bid price of CollabRx's common stock has closed at $1.00 per share or more for the minimum of 10 consecutive trading days. Accordingly, the Company was notified on February 17, 2015 that it had regained compliance and that the matter of the bid price deficiency was closed. The Company remained non-compliant with NASDAQ Listing Rule 5550(b)(1), which requires that it maintain a minimum of $2.5 million in stockholder's equity. The Company will present its plan for regaining compliance in a hearing before the NASDAQ Listing Qualifications Panel that will take place in Washington, D.C. on February 19, 2015. The Company's common stock will continue to trade on The NASDAQ Capital Market pending completion of the hearing process and the expiration of any extension period granted by the Panel.

CollabRx, Inc. and Medytox Solutions, Inc. Enters into Non-Binding Letter of Intent to Negotiate a Potential Business Combination

CollabRx, Inc. and Medytox Solutions, Inc. have entered into a non-binding letter of intent to negotiate a potential business combination. Also, CollabRx and Medytox announced that they have entered into agreements that would secure funding needed by CollabRx to continue to operate while the parties negotiate a potential business combination. The potential business combination is subject to, among other things, due diligence, the execution of a definitive agreement, necessary Board of Directors and stockholder approvals and other customary conditions. CollabRx develops and markets medical information and clinical decision support products and services intended to set a standard for the clinical interpretation of genomics-based, precision medicine in cancer. Medytox Solutions, Inc. is focused on becoming a single-source solution to medical providers for a number of services including clinical laboratory services, electronic health records, laboratory information systems, medical billing services, financial services and other information technology and software solutions.

CollabRx Receives NASDAQ Listing Determination; Intends to Request Hearing

CollabRx, Inc. announced that it received a letter from the NASDAQ Listing Qualifications Staff indicating that, unless the Company timely requests a hearing before the NASDAQ Listing Qualifications Panel (the "Panel"), the Company's securities would be delisted from The NASDAQ Capital Market due to the Company's non-compliance with NASDAQ Listing Rule 5550(b) (1) (the "Rule"). The Company intends to timely request a hearing before the Panel, at which hearing the Company will present its plan to evidence compliance with the Rule, which requires the Company to maintain a minimum of $2.5 million in stockholders' equity. The Company's common stock will continue to trade on The NASDAQ Capital Market under the symbol "CLRX" pending completion of the hearing process and the expiration of any extension period granted by the Panel.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLRX:US $1.35 USD -0.06

CLRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLRX.
View Industry Companies
 

Industry Analysis

CLRX

Industry Average

Valuation CLRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 10.0x
Price/Book 3.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 22.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact COLLABRX INC, please visit www.collabrx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.